AstraZeneca PLC
ZEG.DE
Deutsche Börse160.70
EUR
+0.95
- -
AstraZeneca PLC
ZEG.DE
(Deutsche Börse)
Recent
price
160.70
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- AstraZeneca PLC operates as a leading biopharmaceutical enterprise, dedicated to the exploration, advancement, production, and worldwide distribution of sophisticated prescription medications. The company's diverse portfolio addresses significant disease areas, including a robust presence in oncology with therapies like Tagrisso, Enhertu, Imfinzi, Calquence, and Lynparza. Its cardiovascular, renal, and metabolism segment features key products such as Farxiga/Forxiga, Brilinta/Brilique, and Lokelma. In respiratory and immunology, treatments include Symbicort, Fasenra, Breztri Aerosphere, and Tezspire. Additionally, its rare disease unit, significantly strengthened by the Alexion acquisition, offers solutions such as Ultomiris, Soliris, Strensiq, and Koselugo. The company also provides vital vaccines and immune therapies, including Beyfortus and FluMist, and gastroenterology treatments like Nexium. Serving a global patient population, AstraZeneca reaches primary and specialty care practitioners across the United Kingdom, other European nations, the Americas, Asia, Africa, and Australasia through an extensive network of distributors and local offices. The firm actively engages in strategic partnerships to propel scientific innovation, exemplified by its collaboration with CSPC Pharmaceuticals Group on AI-driven drug discovery for chronic conditions, and its alliance with Tempus to develop oncology foundation models. Recent advancements include FDA approvals for Enhertu in HR-positive, HER2-low breast cancer, Fasenra for eosinophilic granulomatosis with polyangiitis, Tezspire for chronic rhinosinusitis with nasal polyps, Imfinzi for muscle-invasive bladder cancer, and Koselugo for adult neurofibromatosis type 1. AstraZeneca maintains a substantial research and development pipeline, comprising nearly 200 projects, with over 20 new molecular entities in late-stage development, underscoring its commitment to delivering new medicines and achieving an ambitious revenue target of $80 billion by 2030. The company continues to make significant strategic investments, notably a planned $50 billion in the United States by 2030 to expand manufacturing capabilities, including increasing biologics production and bringing rare disease portfolio manufacturing onshore in Maryland and establishing a new drug substance facility in Virginia. Incorporated in 1992, the company adopted its current name, AstraZeneca PLC, in April 1999 and is headquartered in Cambridge, United Kingdom.